Reproducibility, reliability and validity of population-based administrative health data for the assessment of cancer non-related comorbidities

被引:62
作者
Maringe, Camille [1 ]
Fowler, Helen [1 ]
Rachet, Bernard [1 ]
Luque-Fernandez, Miguel Angel [1 ]
机构
[1] London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Canc Survival Grp, London, England
来源
PLOS ONE | 2017年 / 12卷 / 03期
关键词
CO-MORBIDITY; CHARLSON; INDEX; SURVIVAL; IMPACT; STAGE; LUNG; MORTALITY; DIAGNOSIS;
D O I
10.1371/journal.pone.0172814
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background Patients with comorbidities do not receive optimal treatment for their cancer, leading to lower cancer survival. Information on individual comorbidities is not straightforward to derive from population-based administrative health datasets. We described the development of a reproducible algorithm to extract the individual Charlson index comorbidities from such data. We illustrated the algorithm with 1,789 laryngeal cancer patients diagnosed in England in 2013. We aimed to clearly set out and advocate the time-related assumptions specified in the algorithm by providing empirical evidence for them. Methods Comorbidities were assessed from hospital records in the ten years preceding cancer diagnosis and internal reliability of the hospital records was checked. Data were right-truncated 6 or 12 months prior to cancer diagnosis to avoid inclusion of potentially cancer-related comorbidities. We tested for collider bias using Cox regression. Results Our administrative data showed weak to moderate internal reliability to identify comorbidities (ICC ranging between 0.1 and 0.6) but a notably high external validity (86.3%). We showed a reverse protective effect of non-cancer related Chronic Obstructive Pulmonary Disease (COPD) when the effect is split into cancer and non-cancer related COPD (Age-adjusted HR: 0.95, 95% CI:0.7-1.28 for non-cancer related comorbidities). Furthermore, we showed that a window of 6 years before diagnosis is an optimal period for the assessment of comorbidities. Conclusion To formulate a robust approach for assessing common comorbidities, it is important that assumptions made are explicitly stated and empirically proven. We provide a transparent and consistent approach useful to researchers looking to assess comorbidities for cancer patients using administrative health data.
引用
收藏
页数:14
相关论文
共 48 条
  • [1] Impact of Acquired Comorbidities on All-Cause Mortality Rates Among Older Breast Cancer Survivors
    Ahern, Thomas P.
    Lash, Timothy L.
    Thwin, Soe Soe
    Silliman, Rebecca A.
    [J]. MEDICAL CARE, 2009, 47 (01) : 73 - 79
  • [2] Influence of Medical Comorbidities on the Presentation and Outcomes of Stage I-III None-Small-Cell Lung Cancer
    Ahn, Daniel H.
    Mehta, Nishi
    Yorio, Jeffrey T.
    Xie, Yang
    Yan, Jingsheng
    Gerber, David E.
    [J]. CLINICAL LUNG CANCER, 2013, 14 (06) : 644 - 650
  • [3] Akushevich Igor, 2011, ISRN Oncol, V2011, P415790, DOI 10.5402/2011/415790
  • [4] Mortality, Cancer, and Comorbidities Associated With Chronic Pancreatitis: A Danish Nationwide Matched-Cohort Study
    Bang, Ulrich Christian
    Benfield, Thomas
    Hyldstrup, Lars
    Bendtsen, Flemming
    Jensen, Jens-Erik Beck
    [J]. GASTROENTEROLOGY, 2014, 146 (04) : 989 - U528
  • [5] The Best Use of the Charlson Comorbidity Index With Electronic Health Care Database to Predict Mortality
    Bannay, Aurelie
    Chaignot, Christophe
    Blotiere, Pierre-Olivier
    Basson, Mickael
    Weill, Alain
    Ricordeau, Philippe
    Alla, Francois
    [J]. MEDICAL CARE, 2016, 54 (02) : 188 - 194
  • [6] Bernardini Judith, 2004, Adv Perit Dial, V20, P125
  • [7] Prognostic Impact of Comorbidity among Long-Term Breast Cancer Survivors: Results from the LACE Study
    Braithwaite, Dejana
    Moore, Dan H.
    Satariano, William A.
    Kwan, Marilyn L.
    Hiatt, Robert A.
    Kroenke, Candyce
    Caan, Bette J.
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2012, 21 (07) : 1115 - 1125
  • [8] BRAMER G R, 1988, World Health Statistics Quarterly, V41, P32
  • [9] Does comorbidity explain the ethnic inequalities in cervical cancer survival in New Zealand? A retrospective cohort study
    Brewer, Naomi
    Borman, Barry
    Sarfati, Diana
    Jeffreys, Mona
    Fleming, Steven T.
    Cheng, Soo
    Pearce, Neil
    [J]. BMC CANCER, 2011, 11
  • [10] CDC, 2001, Morbidity and Mortality Weekly Report, V50, P1